

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)



(10) International Publication Number
WO 2023/060089 A3

(51) International Patent Classification:
C12N 9/12 (2006.01) C12N 15/90 (2006.01)

MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2022/077549

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(22) International Filing Date:
04 October 2022 (04.10.2022)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/252,028 04 October 2021 (04.10.2021) US
63/312,928 23 February 2022 (23.02.2022) US
63/369,863 29 July 2022 (29.07.2022) US

(88) Date of publication of the international search report:
25 May 2023 (25.05.2023)

(71) Applicant: POSEIDA THERAPEUTICS, INC.
[US/US]; 9390 Towne Centre Drive, Suite 200, San Diego,
CA 92121 (US).

(72) Inventors: ZHANG, Dongyang; 9390 Towne Centre Drive,
Suite 200, c/o Poseida Therapeutics, Inc., San Diego,
CA 92121 (US). MADISON, Blair, B.; 9390 Towne Centre
Drive, Suite 200, c/o Poseida Therapeutics, Inc., San
Diego, CA 92121 (US). LUCAS, Joseph, S.; 9390 Towne
Centre Drive, Suite 200, c/o Poseida Therapeutics, Inc., San
Diego, CA 92121 (US). BATALOV, Olga; 9390 Towne
Centre Drive, Suite 200, c/o Poseida Therapeutics, Inc.,
San Diego, CA 92121 (US). VALDERRAMA, J., Andres;
9390 Towne Centre Drive, Suite 200, c/o Poseida Therapeu-
tics, Inc., San Diego, CA 92121 (US).

(74) Agent: PAVAO, Matthew et al.; Cooley LLP, 1299 Penn-
sylvania Ave., Suite 700, Washington, DC 20004 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: TRANSPOSASES AND USES THEREOF

(57) Abstract: This disclosure generally relates to transposase domains, in particular, transposase domains comprising amino terminal deletions, as well as transposase domains forming obligate heterodimers and transposase domains comprising DNA targeting domains.

WO 2023/060089 A3